On May 12, Michael McCallister, Director at Zoetis (NYSE: ZTS), purchased 3,000 shares of the company, totaling $233,273. This insider transaction, disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission, indicates McCallister's confidence in Zoetis's future despite a 1.63% drop in share price to $75.69. Zoetis specializes in animal health products, earning approximately 35% of its revenue from production animals and 65% from companion animals. The company reported a revenue growth rate of 2.91% as of March 31, 2026, although this figure lags behind its industry peers. Financial metrics reveal a gross margin of 71.66% and an EPS of 1.42, both below industry averages. Additionally, Zoetis's debt-to-equity ratio of 2.86 suggests significant financial leverage. The stock's current P/E ratio of 12.61 and a P/S ratio of 3.53 indicate potential undervaluation, presenting an opportunity for investors. Insider purchases can signal optimism, but investors should consider a range of factors before making decisions.